<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:cc="http://cyber.law.harvard.edu/rss/creativeCommonsRssModule.html">
    <channel>
        <title><![CDATA[Stories by Syed Usman on Medium]]></title>
        <description><![CDATA[Stories by Syed Usman on Medium]]></description>
        <link>https://medium.com/@syedu0600?source=rss-86d9421bcccd------2</link>
        <image>
            <url>https://cdn-images-1.medium.com/fit/c/150/150/1*dmbNkD5D-u45r44go_cf0g.png</url>
            <title>Stories by Syed Usman on Medium</title>
            <link>https://medium.com/@syedu0600?source=rss-86d9421bcccd------2</link>
        </image>
        <generator>Medium</generator>
        <lastBuildDate>Fri, 20 Nov 2026 14:10:33 GMT</lastBuildDate>
        <atom:link href="https://medium.com/@syedu0600/feed" rel="self" type="application/rss+xml"/>
        <webMaster><![CDATA[yourfriends@medium.com]]></webMaster>
        <atom:link href="http://medium.superfeedr.com/" rel="hub"/>
        <item>
            <title><![CDATA[Citi Pharma (CPHL)— A Potential Gem In Pakistan’s API Industry & Why I Will Probably Opt Out Of It.]]></title>
            <link>https://medium.com/@syedu0600/citi-pharma-cphl-a-potential-gem-in-pakistans-api-industry-why-i-probably-will-opt-out-of-it-1ff49276ebd8?source=rss-86d9421bcccd------2</link>
            <guid isPermaLink="false">https://medium.com/p/1ff49276ebd8</guid>
            <category><![CDATA[psx]]></category>
            <category><![CDATA[pakistan-stock-exchange]]></category>
            <category><![CDATA[value-investing]]></category>
            <category><![CDATA[citi-pharma]]></category>
            <category><![CDATA[company]]></category>
            <dc:creator><![CDATA[Syed Usman]]></dc:creator>
            <pubDate>Thu, 20 Mar 2025 11:41:53 GMT</pubDate>
            <atom:updated>2025-03-20T12:01:02.438Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/700/1*62XzVVn2rw4QdCi0hP9ozA.jpeg" /></figure><p>I don’t like wasting time mentioning formal crap and doing small talk in my work, so let’s just get into what I’ve gathered on Citi Pharma and some ups and downs this company could face in the coming years.</p><p>Citi Pharma (CPHL) has had some buzz in Pakistan’s investing community due to its incredible returns in the last 1–2 years. (280%) I’m personally invested in this company. However, as of right now and going forward, here are some challenges Citi Pharma can face as well as potential solutions I can suggest from my limited knowledge:</p><ul><li>First and foremost, whenever a value investor picks a stock, the first question he/she should ask himself is “WHY?”. Around the time I was researching good Pharma companies to invest in Pakistan, I happened to have gone through annual, half-yearly, and quarterly reports from a handful of different Pharma companies in Pakistan. (Haleon, Highnoon, GSK…etc) and one thing all these companies mentioned was their growing reliance on imported APIs and how Pakistan’s pharma industry can become constricted if no local API initiatives are taken or supported by the GOP.</li><li>There, I saw a (POTENTIAL) opportunity in Citi Pharma as it’s probably one of the two prominent API manufacturing companies in Pakistan. As of right now, Citi Pharma’s stock is relatively stable around the 90–100 range. However, I see great potential upside in it due to these vigorous expansion plans:</li></ul><p>1: The company plans to set up API plants in Indonesia (increasing capacity to 10,000 metric tons/annum of paracetamol and 1800 metric tons/annum of amoxilin). This plant should commence operation by 2027.</p><p>2: Plans to set up a plant in Saudia (6,000 metric tons/annum paracetamol and 1500 amoxicillin). This plant should commence operation by 2027.</p><p>3: Partnered with a Chinese pharma company to enhance API production by 2030. Also plans to step into the biotech and biosciences field by this time.</p><p>4: Plans to step into the retail market, meaning the company can sell finished products directly to people and lower dependency on API sales. This is a major step considering the retail market of drugs and medicines is huge and it could be a game changer for the company. Selling directly in the retail market could also result in substantially improved margins since companies like GSK, Haleon, Abbott, Searle and etc purchase APIs on a fixed price basis from Citi Pharma.</p><p>Now, my problem with the company is regarding its confusing expansion plans. On one hand, it’s doing wonderful work by making strategic partnerships and growing what it needs to grow the most which is its production capacity. However, the company also plans on diversifying its portfolio through a REIT project and is also in the works of setting up a hospital facility in Lahore.</p><p>Personally, my vision has always been to invest in what I fully understand and these new projects and diversification initiatives by the company don’t make sense to me. Pakistani Pharma companies are largely dependent on imported APIs which can ruin margins if dollar cost rises again against PKR, and yet Citi Pharma wants to make a Citi Reit and make a hospital facility? Why are they not 110% dedicated to growing their API segment which would positively impact the entire local pharma industry?</p><p>For now, the company should:</p><ul><li>Shift their entire focus to growing their API segment by setting up more API manufacturing plants.</li><li>Work on their strategic partnerships with full attention to get new API expansion plans up and running as quickly as possible.</li><li>Devise plans to step into the retail market and execute them by introducing high-demand drugs and medicines.</li></ul><p>In the next few quarters (short to medium-term) I expect profitability to decline slightly due to their expansion plans. Keep in mind that any delays in these expansion plans could result in the company issuing right shares to raise capital to complete their expansion plans. This can dilute quarterly EPS and send it down the drain temporarily.</p><p>What shareholders/potential investors should keep an eye on in the coming company reports:</p><ul><li>Operating margins</li><li>Any talks about the API segment expansion plans.</li><li>Partnerships, and how they will help the company enhance API production.</li></ul><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=1ff49276ebd8" width="1" height="1" alt="">]]></content:encoded>
        </item>
    </channel>
</rss>